Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced a presentation at the 27th European Academy of Dermatology & Venereology Congress (EADV), to be held September 12-16, 2018 in Paris.

Details for the presentation are as follows:

Oral Presentation:
Title:	"Clinically Meaningful Reduction of Itch and Improvement in Multiple Quality of Life Measures in Hemodialysis Patients with Moderate-to-Severe Pruritus Following Treatment with Difelikefalin”
Date / Time:	Thursday, September 13, 2018, 15:00 - 16:30 CET
Presenter:	Frédérique Menzaghi, Ph.D., Senior Vice President, Research & Development, Cara Therapeutics

For information about EADV, visit https://eadvparis2018.org.

About Cara Therapeutics 

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by KORSUVATM (CR845/difelikefalin), a first-in-class kappa opioid receptor agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). KORSUVA is currently being investigated in global Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, in a recently completed Phase 2/3 trial in post-operative patients, I.V. CR845/difelikefalin has demonstrated reduction in moderate-to-severe pain, while also reducing the incidence and intensity of nausea and vomiting throughout the post-operative period.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:Michael SchaffzinStern Investor [e-mail]

MEDIA CONTACT:Annie Starr6 Degrees973-415-8838 [e-mail]